Menu Search
Equities

Azitra Inc

AZTR:ASQ

Azitra Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.55
  • Today's Change-0.049 / -8.18%
  • Shares traded412.87k
  • 1 Year change-98.97%
  • Beta--
Data delayed at least 15 minutes, as of Sep 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Azitra Inc had net income fall 5.65% from a loss of 10.68m to a larger loss of 11.28m despite a 141.55% increase in revenues from 284.00k to 686.00k.
Gross margin--
Net profit margin-2,440.46%
Operating margin-2,497.69%
Return on assets-145.30%
Return on equity-222.30%
Return on investment-194.72%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Azitra Inc fell by 1.70m. Cash Flow from Financing totalled 5.98m or 872.30% of revenues. In addition the company used 7.36m for operations while cash used for investing totalled 318.26k.
Cash flow per share-2.77
Price/Cash flow per share--
Book value per share1.80
Tangible book value per share1.57
More ▼

Balance sheet in USDView more

Azitra Inc uses little debt in its capital structure as supported by a debt to capital ratio of 1.91%.
Current ratio0.7681
Quick ratio--
Total debt/total equity0.0195
Total debt/total capital0.0191
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.